Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
Merck
Boehringer Ingelheim
McKinsey

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

CHILDREN'S ALLEGRA ALLERGY Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Children's Allegra Allergy patents expire, and when can generic versions of Children's Allegra Allergy launch?

Children's Allegra Allergy is a drug marketed by Sanofi Aventis Us and is included in three NDAs. There are two patents protecting this drug.

This drug has sixty-one patent family members in thirty-nine countries.

The generic ingredient in CHILDREN'S ALLEGRA ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and twelve suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Children's Allegra Allergy

A generic version of CHILDREN'S ALLEGRA ALLERGY was launched as fexofenadine hydrochloride by BARR on December 14th, 2019.

Drug patent expirations by year for CHILDREN'S ALLEGRA ALLERGY
Recent Litigation for CHILDREN'S ALLEGRA ALLERGY

Identify potential future generic entrants

District Court Litigation
Case NameDate
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13
AVENTIS PHARMACEUTICALS INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD.2009-10-09
ALBANY MOLECULAR RESEARCH, INC. v. DR. REDDY'S LABORATORIES, LTD.2009-09-09

See all CHILDREN'S ALLEGRA ALLERGY litigation

Pharmacology for CHILDREN'S ALLEGRA ALLERGY
Synonyms for CHILDREN'S ALLEGRA ALLERGY
(+-)-p-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-alpha-methylhydratropic acid hydrochloride
138452-21-8
153439-40-8
2-(4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)PIPERIDIN-1-YL)BUTYL)PHENYL)-2-METHYLPROPANOIC ACID HCL
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hydr
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hydrochloride
2-(4-{1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl}-phenyl)-2-methyl-propionic acid; hydrochloride
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid hydrochloride
2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropans
2-[4-[1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]-butyl]phenyl]-2-methyl-propanoicacidhydrochloride
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid hydrochloride
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid;hydrochloride
2S068B75ZU
4-[(4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
4-[4-[4-(Hydroxydiphenylmethyl)-1-pieridinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid hydrochloride
452F218
4CH-009369
A3371
AB0011964
AB07499
AC-24745
AC1L1Y6V
AC1Q3E6W
AKOS015907422
Allegra
Allegra (TN)
Allegra Allergy
Allegra Flash
Allegra Hives
Allegra OD
alpha-(4-(1-carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol
Altiva
ANW-43654
Benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride
Benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride, (+-)-
BIM-0050472.0001
BR-72915
C32H39NO4.HCl
C32H40ClNO4
Carboxyterfenadine hydrochloride
CAS-153439-40-8
CCG-213275
CF0042
CHEBI:5051
CHEMBL1200618
Children's Allegra Hives
CPD000718798
CS-4483
CTK8B4006
D00671
DSSTox_CID_28642
DSSTox_GSID_48716
DSSTox_RID_82912
DTXSID5048716
F0698
Fexofenadine (hydrochloride)
FEXOFENADINE HCL
Fexofenadine HCl, Pharmaceutical Secondary Standard; Certified Reference Material
FEXOFENADINE HYDROCHLORIDE
Fexofenadine hydrochloride (JP17/USAN)
Fexofenadine hydrochloride [USAN:USP]
Fexofenadine hydrochloride, >98% (HPLC)
Fexofenadine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Fexofenadine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Fexofenadine, HCl
FexofenadineHydrochloride
Fexofenidine hydrochloride
FT-0631183
HY-B0801A
J-505843
J10191
KB-222041
KS-000011XN
KS-1057
LS-173025
M-016455-O
MDL 16,455A
MDL 16.455
MDL 16455
MDL 16455 hydrochloride
MDL-16455
MDL-16455A
MFCD00865710
MLS001306422
MLS001332493
MLS001332494
MolPort-003-666-536
NC00724
NCGC00015453-02
NCGC00015453-05
NCGC00015453-08
NCGC00092389-01
NCGC00095906-01
NCGC00095906-02
NSC-758678
NSC758678
Pharmakon1600-01504179
RP17816
RRJFVPUCXDGFJB-UHFFFAOYSA-N
RTR-006346
S-5170
s3208
SAM002700173
SCHEMBL40914
SMR000718798
SPECTRUM1504179
SR-01000075889
SR-01000075889-6
SW199568-2
Telfast
Terfenadine carboxylate hydrochloride
Terfenidine carboxylate hydrochloride
Tox21_113125
Tox21_113125_1
TR-006346
UNII-2S068B75ZU
Z2210694607
Paragraph IV (Patent) Challenges for CHILDREN'S ALLEGRA ALLERGY

US Patents and Regulatory Information for CHILDREN'S ALLEGRA ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride SUSPENSION;ORAL 201373-001 Jan 24, 2011 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-002 Jan 24, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-005 Jan 24, 2011 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CHILDREN'S ALLEGRA ALLERGY

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
Harvard Business School
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.